Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Plasma osteopontin levels in prediction of prognosis in acute myocardial infarction.

Okyay K, Tavil Y, Sahinarslan A, Tacoy G, Turfan M, Sen N, Gurbahar O, Boyaci B, Yalcin R, Demirkan D, Cengel A.

Acta Cardiol. 2011 Apr;66(2):197-202.

PMID:
21591578
2.

Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Haeck JD, Verouden NJ, Kuijt WJ, Koch KT, Van Straalen JP, Fischer J, Groenink M, Bilodeau L, Tijssen JG, Krucoff MW, De Winter RJ.

Am J Cardiol. 2010 Apr 15;105(8):1065-9. doi: 10.1016/j.amjcard.2009.12.003. Epub 2010 Feb 20.

PMID:
20381654
3.

Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?

Ezekowitz JA, Théroux P, Welsh R, Bata I, Webb J, Armstrong PW.

Can J Physiol Pharmacol. 2007 Jan;85(1):173-8.

PMID:
17487257
4.
5.

Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.

Buchner S, Debl K, Barlage S, Griese D, Fredersdorf S, Jeron A, Lubnow M, Müller T, Muders F, Holmer S, Riegger GA, Luchner A.

Clin Chem Lab Med. 2010 Jun;48(6):875-81. doi: 10.1515/CCLM.2010.164.

PMID:
20441480
6.

Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction.

Kaya MG, Yalcin R, Okyay K, Poyraz F, Bayraktar N, Pasaoglu H, Boyaci B, Cengel A.

Tex Heart Inst J. 2012;39(4):500-6.

7.

Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.

Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, Schönland SO, Schnabel PA, Schuster T, Röcken C, Giannitsis E, Katus HA, Frey N.

Amyloid. 2014 Sep;21(3):202-10. doi: 10.3109/13506129.2014.940457. Epub 2014 Jul 9.

PMID:
25007036
8.

High osteopontin levels predict long-term outcome after STEMI and primary percutaneous coronary intervention.

Bjerre M, Pedersen SH, Møgelvang R, Lindberg S, Jensen JS, Galatius S, Flyvbjerg A.

Eur J Prev Cardiol. 2013 Dec;20(6):922-9. doi: 10.1177/2047487313487083. Epub 2013 Apr 23.

PMID:
23613225
9.
10.

Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction.

Steen H, Futterer S, Merten C, Jünger C, Katus HA, Giannitsis E.

J Cardiovasc Magn Reson. 2007;9(5):749-58.

PMID:
17891611
11.

Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.

Björklund E, Jernberg T, Johanson P, Venge P, Dellborg M, Wallentin L, Lindahl B; ASSENT-2 and ASSENT-PLUS Study Groups.

Heart. 2006 Jun;92(6):735-40. Epub 2005 Oct 26.

12.

Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction.

Talwar S, Squire IB, Downie PF, Mccullough AM, Campton MC, Davies JE, Barnett DB, Ng LL.

Eur Heart J. 2000 Sep;21(18):1514-21.

PMID:
10973765
13.

Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.

Byrne RA, Ndrepepa G, Braun S, Tiroch K, Mehilli J, Schulz S, Schömig A, Kastrati A.

Am J Cardiol. 2010 Nov 1;106(9):1212-7. doi: 10.1016/j.amjcard.2010.06.050. Epub 2010 Sep 9.

PMID:
21029815
14.

Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocardial infarction.

Sarullo FM, Gristina T, Brusca I, Serio G, Taormina A, La Chiusa SM, Castello A, Borruso E, Paterna S, Di Pasquale P.

Minerva Cardioangiol. 2007 Apr;55(2):149-55.

PMID:
17342035
15.

Monocyte heterogeneity in myocardial infarction with and without ST elevation and its association with angiographic findings.

Arslan U, Kocaoğlu I, Balci MM, Gülkan B, Falay MY, Temizhan A.

Coron Artery Dis. 2013 Aug;24(5):404-11. doi: 10.1097/MCA.0b013e328361a98c.

PMID:
23612365
16.
17.

N-terminal probrain natriuretic peptide predicts adverse outcomes in acute-myocardial infarction even with preserved left ventricular ejection fraction.

Puri A, Narain VS, Mehrotra S, Dwivedi SK, Saran RK, Puri VK.

Indian Heart J. 2006 Mar-Apr;58(2):138-43.

PMID:
18989058
18.

Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Hall TS, Hallén J, Krucoff MW, Roe MT, Brennan DM, Agewall S, Atar D, Lincoff AM.

Am Heart J. 2015 Feb;169(2):257-265.e1. doi: 10.1016/j.ahj.2014.10.015. Epub 2014 Nov 4.

PMID:
25641535
19.

[NT-proBNP and echocardiography for long-term left ventricular function assessment after acute myocardial infarction treated with primary angioplasty].

Swiatkiewicz I, Grubecki A, Koziński M, Fabiszak T, Białoszyński T, Sukiennik A, Kubica J.

Pol Merkur Lekarski. 2006 Mar;20(117):289-92. Polish.

PMID:
16780257
20.

Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.

Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, Sinnaeve PR, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT IV-PCI investigators.

Am Heart J. 2010 Jan;159(1):131-40. doi: 10.1016/j.ahj.2009.11.001.

PMID:
20102879

Supplemental Content

Support Center